Add high WBC count to the list of risk factors for cancer

Article

Postmenopausal women with a high white blood cell count are more likely to develop cancer. . .

Postmenopausal women with a white blood cell (WBC) count of 6.80–15.00×109 cells/L are more likely to develop invasive breast cancer, colorectal cancer, endometrial cancer, and lung cancer, according to the results of a recent prospective study. The findings add to the mounting data that point to a causal link between inflammation and these types of tumors.

The study involved 40 centers and over 140,000 women aged 50 to 79 years. The authors calculated that compared to women with WBC counts in the lowest quartile (2.50–4.79×109 cells/L), those in the highest quartile (6.8–15.00×109 cells/L) had a hazard ratio for invasive breast cancer of 1.15 (95% CI, 1.04–1.26), for colorectal cancer of 1.19 (95% CI, 1.00–1.41), for endometrial cancer of 1.42 (95% CI, 1.12–1.79), and for lung cancer of 1.63 (95% CI, 1.35–1.97). The findings remained significant even after excluding cancers that were diagnosed during the first 2 years of follow-up and after limiting analysis to nonsmoking participants.

The researchers also found that higher WBC counts were significantly associated with a high risk of breast, lung, and overall cancer mortality.

Recent Videos
HPV self-collection: Benefits, limitations, and future implications | Image Credit: forhers.com
Improving pediatric HPV vaccination rates: Early initiation and addressing disparities | Image Credit: blog.nemours.org.
New cervical cancer screening guidelines: What practitioners needs to know | Image Credit: forhers.com
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.